Instrument Inactif

Communiqués Newron Pharmaceuticals SpA CBOE EUROPE EQUITIES

Actions

0QOI

IT0004147952

Cours en clôture CBOE EUROPE EQUITIES Autres places de cotation
- ^CHF	-

13/05	Newron Pharmaceuticals S.P.A présente des données supplémentaires convaincantes documentant l'efficacité de l'evenamide dans l'étude pivot 008A chez les patients schizophrènes répondant mal au traitement.	CI
13/05	Newron détaille son succès d'étape contre la schizophrénie	AW

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

DD: Newron Pharmaceuticals S.p.A.: Stefan Weber, buy	27/06	EQ
DD: Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy	26/06	EQ
DD: Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy	26/06	EQ
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City	25/06	EQ
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City	25/06	BU
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City	18/06	EQ
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City	18/06	BU
DD: Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy	18/06	EQ
DD: Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy	18/06	EQ
DD: Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy	17/06	EQ
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City	05/06	BU
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City	05/06	EQ
Save the Date: June 25, Newron Investor Day: Evenamide for poor responders and patients with treatment-resistant Schizophrenia, a Roadmap to Registration	31/05	PU
DD: Newron Pharmaceuticals S.p.A.: Non-Exec. Director Luca Benatti, sell	22/05	EQ
Newron Pharmaceuticals S p A : Report (Corporate May 2024 web2)	21/05	PU
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients	13/05	BU
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients	13/05	EQ
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	30/04	BU
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients	30/04	EQ
Newron Pharmaceuticals S p A : announces AGM 2024 results	17/04	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Newron Pharmaceuticals SpA CBOE EUROPE EQUITIES

Actions

0QOI

IT0004147952

Communiqués

Filtres